Revenue segments as reported by the company.

U.S. Pharmaceutical

Prescription Technology Solutions

Medical-Surgical Solutions

International

Corporate

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, distribution, general, and administrative expenses

Claims and litigation charges, net

Restructuring, impairment, and related charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

McKesson

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, including Multi-Client Central Fill as a Service, to serve biopharma and life sciences partners and patients. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

McKesson reports robust fiscal 2023 performance and focuses on sustainability

McKesson's Q4 fiscal 2023 earnings call highlighted strong financial performance, strategic priorities, and a focus on sustainability and employee recognition. The company faces challenges related to operational efficiencies and managing potential impacts from industry dynamics. However, it remains optimistic about opportunities for long-term growth and partnerships in the oncology space.

McKesson reports strong Q1 performance and anticipates sustained growth

McKesson's Q1 fiscal 2024 earnings call showcased strong financial performance, with a focus on prescription volume growth and expansion in the U.S. Oncology Network. The company faces potential fluctuations and timing challenges in its RxTS business but expects to benefit from volume-related factors and continual development. Overall, McKesson is well-positioned for sustainable growth and value creation.

McKesson excels in Q3, eyes oncology growth and sustainability

McKesson's Q3 performance was strong, with raised guidance and progress in strategic priorities.
The company's strengths lie in its focus on oncology, sustainability initiatives, and operational performance.
Challenges include macroeconomic factors, biosimilar management, and margin improvement strategies.
Opportunities in oncology growth, biosimilars, and strategic partnerships pave the way for future success.

McKesson reports robust earnings, poised for sustainable growth in healthcare

McKesson's Q4 2023 earnings call highlighted strong financial performance, strategic advancements, and a commitment to driving sustainable growth in key healthcare segments.
The company's focus on efficiency, sustainability, and employee engagement underpins its competitive strengths and resilience in a dynamic healthcare landscape.
While challenges such as industry fluctuations and regulatory dynamics exist, McKesson's strategic positioning, diverse business lines, and growth opportunities position it for continued success.
By leveraging opportunities in service expansion, biosimilars, and market trends, McKesson aims to enhance patient outcomes, drive revenue growth, and maintain its leadership in the healthcare services sector.

McKesson exceeds Q1 expectations, focuses on supply chain efficiency

McKesson delivered strong first-quarter results, exceeding revenue and earnings expectations.
The company's focus on enhancing supply chain efficiency and expanding relationships with manufacturers is driving growth.
Challenges include non-linear investments and the impact of 340B on pharmaceutical distribution business.
Opportunities lie in benefiting from volume-related factors, supporting product life cycles, and expanding oncology solutions.

McKesson excels in Q2, anticipates growth amid strategic investments

McKesson's Q2 performance reflects strong revenue growth and operational excellence across key segments.
The company's focus on employee well-being, technology solutions, and strategic investments positions it for continued success.
While facing competitive challenges in generics procurement, McKesson maintains stability and customer-centric supply.
Anticipated growth opportunities in fiscal 2024 and beyond underscore McKesson's commitment to innovation and operational efficiency.

McKesson reports robust Q3 earnings, eyes growth through strategic investments

McKesson's Q3 performance reflects strong revenue and earnings growth, supported by strategic initiatives and investments in key segments. While facing challenges like patient visit volumes and margin pressures, the company remains focused on driving sustainable growth and value delivery. Opportunities for growth through technology investments and segment expansions position McKesson for future success.

McKesson reports robust Q4 results, eyes growth in oncology services

McKesson's strong performance in Q4 '24 underscores its leadership in oncology and biopharma services, supported by strategic investments in AI and a new partnership with Optum. While facing challenges in pricing dynamics and 3PL business growth, the company is well-positioned to capitalize on opportunities in inorganic growth, AI utilization, and health equity initiatives.

McKesson reports solid Q1 growth, focuses on pharma innovation

McKesson's Q1 2025 showed solid revenue growth and increased earnings per share, driven by strong performance in pharmaceutical segments.
While facing challenges in the Medical-Surgical segment, the company aims to leverage strengths in distribution and technology investments for future growth.
Opportunities lie in capitalizing on pharmaceutical segment performance and driving innovation through technology investments.
Overall, McKesson's outlook for fiscal 2025 remains positive with projected revenue and profit growth.

McKesson posts record revenue, focuses on oncology for sustained growth

McKesson's strong financial performance and raised guidance reflect its resilience and strategic focus on growth.
While facing regulatory and integration challenges, the company's commitment to innovation and employee well-being positions it well for the future.
Opportunities lie in expanding market presence through acquisitions, influencing policy reforms, and optimizing operational efficiencies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

West Pharmaceutical Services

MCK vs. WST: Which Stock Is the Better Value Option?

Let's see if McKesson Corp (MCK) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Choose McKesson Corp (MCK) Stock?

One medical distribution company has been through this before.

When a COVID-19 Vaccine Is Ready, This Company Is Prepared for Action

Amazon.com Inc. (NASDAQ:AMZN) has been one of the most innovative and disruptive companies of this century, with incredible success in areas that lie outside of what has been historically perceived as its core business (book selling).

McKesson: Amazon Will Not Throw This Drug Railroad Off the Tracks

McKesson (MCK) reported earnings 30 days ago. What's next for the stock?

Why Is McKesson (MCK) Up 8.9% Since Last Earnings Report?

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation today announced the launch of Ontada, an oncology technology and insights business designed to support innovation, acceleration, and evidence generation to drive better outcomes for patients with cancer. “Ontada reflects McKesson's continued commitment and investment in the oncology community,” said Brian Tyler, chief executive officer, McKesson. “As one of the largest healthcare companies, McKesson is at the center of care delivery, which pr

McKesson Launches Ontada, an Oncology Technology and Insights Business Dedicated to Help Advance Cancer Research and Care

FedEx

Demonstrating effectiveness is no small task, but the next challenge may be even greater.

Once the FDA Green Lights a Vaccine, This Is the Next Big Hurdle for Investors

Avantor Inc.

CryoPort

Thermo Fisher Scientific

Excited about the Covid-19 vaccines from Pfizer and Moderna? You'll be waiting a long time unless the vaccines can be shipped at 94 degrees below zero.

Ultra-Cold Freezer Makers To Profit From Covid-19 Vaccine Rush

McKesson's share price has reacted negatively on news of Amazon's entry into the pharmacy space. I see this reaction as being unwarranted. Meanwhile, McKesson continues to show operating strength, and the tentative opioid litigation settlement removes an overhang.

McKesson: A Buy The Dip Opportunity, With 26% Upside Potential

McKesson shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. The post Health Care Products Giant McKesson Earns Key Rating Upgrade appeared first on Investor's Business Daily.

Health Care Products Giant McKesson Earns Key Rating Upgrade

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE:MCK) today announced that the company has appointed Dr. Kelvin A. Baggett to the newly created role of chief impact officer, effective November 30, 2020. “We are delighted to welcome Kelvin to our executive leadership team,” said Brian Tyler, CEO, McKesson Corporation. “He has been recognized nationally for his leadership work to address many of the key healthcare challenges and related societal causes that are of critical importance fo

McKesson Appoints Dr. Kelvin A. Baggett to Chief Impact Officer

AbbVie

Aspen Technology Inc

Alibaba

Bristol-Myers

British American Tobacco

Cboe Global Markets

Cisco Systems

eBay

Altria

Oracle

Polaris

Philip Morris

SEI Investments

T. Rowe Price Group

Optimism about effective vaccines coming soon have sent the market back to record highs, ending the pullback. For the rest of the year, the pandemic is expected to continue getting worse. JPMorgan estimates a 20% to 25% probability of a double-dip recession and a 22% bear market.

The 15 Highest Quality Blue Chips To Buy With Market At All-Time Highs

McKesson Corporation (MCK) CEO Brian Tyler on Q2 2021 Results - Earnings Call Transcript

McKesson, which the U.S. government has tabbed to distribute the Covid-19 vaccines, posted quarterly earnings that easily topped views and hiked its earnings outlook, and MCK stock rose. The post Covid Vaccine Distributor McKesson Hikes Guidance, Stock Jumps appeared first on Investor's Business Daily.

Covid Vaccine Distributor McKesson Hikes Guidance, Stock Jumps

McKesson Corporation's (MCK) CEO Brian Tyler on Q2 2021 Results - Earnings Call Transcript

McKesson's (MCK) fiscal second-quarter 2021 results benefit from strong segmental performance.

McKesson (MCK) Q2 Earnings and Revenues Surpass Estimates

McKesson Corp said on Tuesday it and two other drug distributors could be expected pay up to $21 billion for the potential settlement of lawsuits alleging they fueled the U.S. opioid epidemic.

McKesson says potential opioid settlement proposal raised to up to $21 billion

McKesson (MCK) delivered earnings and revenue surprises of 24.03% and 2.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

McKesson (MCK) Q2 Earnings and Revenues Top Estimates

Shares of McKesson Corp. gained 3.99% in premarket trading on Tuesday after it beat earnings expectations for the quarter. The drug distributor had earnings of $627 million, or $3.54 per share, in the second quarter of 2021, compared with a loss of $677 million, or a per-share loss of $3.99, in the same quarter a year ago.

McKesson's shares jump after beating earnings expectations

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE:MCK) today reported results for the second quarter ended September 30, 2020. Fiscal 2021 Second-Quarter Result Summary     Second-Quarter   Year-to-Date ($ in millions, except per share amounts)   FY21   FY20   Change   FY21   FY20   Change Revenues   $ 60,808     $ 57,616     6 %   $ 116,487     $ 113,344     3 %   Income from Continuing Operations1   577     (729 )   179     1,022     (300 )   441     Adjusted Earnings1,2   784     66

McKesson Reports Fiscal 2021 Second-Quarter Results

Walgreens

DEERFIELD, Ill. & IRVING, Texas--(BUSINESS WIRE)--Walgreens Boots Alliance and McKesson announce the completion of their agreement to create a German wholesale joint venture.

Walgreens Boots Alliance and McKesson Complete the Formation of German Wholesale Joint Venture

Yamana Gold

Capital One

International sales accounted for 59 percenDaily Dividend Report: Apple, Capital One Financial, Yamana Gold, AbbVie, Walgreens Boots Alliance, McKessont of the quarter's revenue.

Daily Dividend Report: Apple, Capital One Financial, Yamana Gold, AbbVie, Walgreens Boots Alliance, McKesson

McKesson's (MCK) fiscal second-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

McKesson (MCK) to Post Q2 Earnings: What's in the Offing?

AmerisourceBergen

Align Technology

Becton, Dickinson and Co.

Cardinal Health

Cooper Companies

Henry Schein

Labcorp Holdings Inc

Patterson Companies

DENTSPLY SIRONA

3 Dental Supplies Stocks Set to Shine on the Industry's Upturn

In this article we will check out the progression of hedge fund sentiment towards McKesson Corporation (NYSE:MCK) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have access to expert networks and get tips from industry insiders. They also employ numerous Ivy League graduates and MBAs. Like everyone else, hedge funds perform miserably at times, but their consensus picks have historically outperformed the market after risk adjustments.

News for McKesson Stock (MCK)